BioMedPartners
Venture capitalBasel · Seed–Late Stage · 28 people tracked
Find your way into BioMedPartners
445 people in our graph share verified history with the BioMedPartners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
BiomedVC backs the next generation of European life science entrepreneurs, helping translate scientific innovation from academic labs into venture-backed biotechs developing therapeutics for high-unmet medical needs. The firm makes initial Seed and Series A investments, leads and co-leads rounds, and reserves capital for follow-on financings. It focuses on continental Europe with an emphasis on the DACH region, particularly Switzerland and Germany. BiomedVC continues the legacy of predecessor BioMedPartners, one of the earliest life-science-focused early-stage VCs in continental Europe. The firm is raising its new fund, BiomedInvest IV, and has already built a significant portfolio of biotech start-ups in Switzerland and Germany.
Source: firm website, verified Aug 7, 2026.
Team · 28 people
from the firm's website & curated & public directories
What they invest in
from 8 of 19 portfolio companiesBiotech ×8Healthtech ×7Medical Devices ×5AI & Machine Learning ×2Deep Tech ×2Digital Health ×1Hardware ×1
HQs:Switzerland×1Germany×1France×1Netherlands×1
Investments · 19 tracked
founders shown can be your intro path
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalFrazier Life SciencesJeito CapitalLongitude CapitalNovo HoldingsOrbiMed+5 more
Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.
BiotechDeep TechHealthtechMedical DevicesLeiden, NL
Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)
Co-investorsForbionJeito CapitalBioGeneration VenturesPictet GroupSeroba Life Sciences
Clinical-stage biopharmaceutical company developing RNA therapeutics for cardiac disease.
Co-investorsHadean VenturesInkefSunstone Capital
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsLightspeed Venture PartnersMission BiocapitalPfizer Venture InvestmentsPfizer Venturesredalpine
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life SciencesForbion+2 more
Immunotherapies for T cell-mediated autoimmune conditions via modulation of coronin 1; spin-off from the University of Basel.
Rajesh Jayachandran, MD PhD(Founder)in
Co-investorsKickfundVenture Kick
Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Co-investorsEIR VenturesOxford Science EnterprisesBioGeneration VenturesInkef
TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
Biotech
Co-investorsredalpine
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.
BiotechHealthtech
Hugo Fry(Chief Executive Officer)inChristian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)in
Co-investorsEMBL VenturesBoehringer Ingelheim Venture FundGimvEpidarex Capital
TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation.
BiotechHardwareHealthtechMedical DevicesFrance, FR
Ahmed Elmouelhi(President & CEO)inEsther Gerteis(Senior VP Medical & Regulatory Affairs)inMichael Litzenburger(VP R&D)in
Co-investorsEuropean Investment Bank415 CapitalAndera PartnersBayern KapitalKarista
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersAscenta CapitalFrazier Life SciencesFund+Nextech InvestOCCIDENT+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Allecra Therapeutics GmbHAMAL Therapeutics SADimericon TherapeuticsiDEL Therapeutics GmbHOmnilinX Therapeutics AGPRECIRIX NVSalvina TherapeuticsT-CURX GmbH
Exits · 1
1 acquisitionsTubulis GmbHacq. by Gilead Sciences
Portfolio news
latest coverage across their companiesAlentis · biopharminternational.com · Jun 29, 2026
Noema Pharma · s-ge.com · Nov 4, 2025
Azafaros · siliconcanals.com · May 14, 2025
Frequently asked questions
- How many investments has BioMedPartners made?
- BioMedPartners has 19 tracked investments, 1 of which have exited.
- What stage does BioMedPartners invest at?
- BioMedPartners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What is BioMedPartners's typical check size?
- BioMedPartners typically writes checks of $648K – $6.5M.
- What sectors does BioMedPartners focus on?
- BioMedPartners focuses on Biotech, Healthtech, Medical Devices.
- Where is BioMedPartners located?
- BioMedPartners is headquartered in Basel, CH.
- Does BioMedPartners lead rounds?
- Yes, BioMedPartners leads investment rounds.
- Who does BioMedPartners co-invest with?
- BioMedPartners most often shares deals with Andera Partners, Jeito Capital, CARMA FUND, among 35 tracked co-investors.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.